ANI Pharmaceuticals (ANIP) received final approval from the US Food and Drug Administration for its abbreviated new drug application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths, the company said Wednesday
The product is the generic version of Afinitor Disperz, with US annual sales of the reference product totaling about $123 million based on July 2026 moving annual total IQVIA data, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.